Vivos Therapeutics Completes Private Placement to Bolster Liquidity

Vivos Therapeutics ( (VVOS) ) has issued an announcement.

On March 31, 2026, Vivos Therapeutics, Inc. completed a private placement with V-Co Investors 3 LLC, an affiliate of existing sponsor New Seneca Partners, selling common stock, a pre-funded warrant and Series A and B common stock purchase warrants for a combined cash inflow of $850,000 and conversion of $1.4 million previously advanced under a January 15, 2026 bridge note. The securities, priced at $1.34 per share for compliance with Nasdaq rules and featuring immediate exercisability, anti-dilution protections and ownership caps, require Vivos to register the underlying shares for resale within specified timelines, underscoring the company’s reliance on structured equity financing to bolster liquidity while giving its sponsor potential for increased future ownership.

The warrants carry exercise prices of $1.09 per share, with the Series A warrant expiring in two years and the Series B warrant in five years, while the near-zero exercise price pre-funded warrant remains outstanding until fully exercised. Vivos plans to use the net proceeds for general working capital and has agreed to cover $50,000 of investor legal fees, indicating a continued strategy of investor-aligned capital raising through exempt private offerings under securities laws as it manages dilution limits and long-term funding access.

The most recent analyst rating on (VVOS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.

Spark’s Take on VVOS Stock

According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.

The score is held down primarily by weak financial performance (persistent losses, worsening cash burn, and a more pressured balance sheet) and bearish technical signals (price below key moving averages with negative MACD). Offsetting factors include strong recent revenue growth and a strategic pivot highlighted on the earnings call, but ongoing cost escalation and the need for bridge/equity financing keep risk elevated, while valuation offers limited support due to negative earnings and no dividend.

To see Spark’s full report on VVOS stock, click here.

More about Vivos Therapeutics

Vivos Therapeutics, Inc., a Delaware corporation, operates in the medical and dental therapeutics sector, focusing on treatments that are supported by private equity investors such as New Seneca Partners Inc. The company accesses capital markets through equity and warrant financings listed on the Nasdaq Stock Market LLC to fund its ongoing operations and general working capital needs.

Average Trading Volume: 122,327

Technical Sentiment Signal: Sell

Current Market Cap: $13.82M

See more insights into VVOS stock on TipRanks’ Stock Analysis page.